文献速递骨质疏松与钙磷/甲状旁腺

绝经后骨质疏松女性接受地舒单抗治疗10年:3期随机FREEDOM试验及其开放标签扩展研究结果

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-05-22

FREEDOM试验纳入7808例60-90岁绝经后骨质疏松女性,随机接受地舒单抗60 mg皮下注射或安慰剂每6个月1次共3年;4550例进入开放标签扩展(长期组2343例、交叉组2207例)。地舒单抗暴露最长10年期间不良事件年发生率从165.3降至95.9/100参与者年,严重不良事件率稳定在11.5-14.4/100参与者年,新发椎体骨折年发生率0.90%-1.86%,骨密度持续升高未见平台期。

要点

  • 地舒单抗暴露最长10年期间不良事件年发生率由165.3降至95.9/100参与者年,严重不良事件率维持在11.5-14.4/100参与者年。
  • 扩展期新发椎体骨折年发生率0.90%-1.86%,非椎体骨折0.84%-2.55%,与FREEDOM前3年地舒单抗组相似且低于虚拟长期安慰剂队列的预计值。
  • 长期组腰椎骨密度较FREEDOM基线升高21.7%,全髋9.2%,股骨颈9.0%,桡骨三分之一处2.7%。

核心结论

  • 地舒单抗治疗最长10年与较低的不良事件发生率相关,骨折发生率低于原试验期间观察到的水平,骨密度持续升高且未见平台期。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照3期FREEDOM试验,在北美、欧洲、拉丁美洲和大洋洲214个中心纳入60-90岁绝经后骨质疏松女性,按1:1随机分为每6个月皮下注射地舒单抗60 mg组或安慰剂组,共3年。
  • 完成FREEDOM且未中断治疗、未遗漏超过1次研究药物剂量的参与者可进入7年开放标签扩展研究,所有参与者均接受地舒单抗。
  • FREEDOM于2004年8月3日至2005年6月1日纳入7808例女性;5928例(76%)符合扩展研究入组条件,其中4550例(77%)于2007年8月7日至2008年6月20日入组(长期组2343例,交叉组2207例)。
  • 2626例女性完成扩展研究(长期组1343例,交叉组1283例);数据代表长期组最长10年、交叉组最长7年的地舒单抗暴露。
  • 安全性分析纳入FREEDOM或扩展研究中至少接受1剂研究药物的全部参与者,疗效分析纳入进入扩展研究且有观察数据的全部参与者,分析按FREEDOM随机分组进行。

主要发现

  • 所有接受地舒单抗者的不良事件年暴露调整参与者发生率在10年间从165.3降至95.9/100参与者年。
  • 严重不良事件率随时间总体稳定,在11.5-14.4/100参与者年之间波动。
  • 扩展研究期间长期组和交叉组各发生1例非典型股骨骨折;长期组报告7例颌骨坏死,交叉组6例。
  • 扩展研究期间新发椎体骨折年发生率(0.90%-1.86%)和非椎体骨折年发生率(0.84%-2.55%)保持较低,与FREEDOM前3年地舒单抗组观察到的发生率相似,且低于虚拟长期安慰剂队列的预计发生率。
  • 长期组骨密度较FREEDOM基线升高:腰椎21.7%、全髋9.2%、股骨颈9.0%、桡骨三分之一处2.7%;交叉组骨密度较扩展研究基线升高:腰椎16.5%、全髋7.4%、股骨颈7.1%、桡骨三分之一处2.3%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term safety and efficacy of osteoporosis treatment are important because of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of denosumab, which is widely used for the treatment of postmenopausal women with osteoporosis. METHODS: In the multicentre, randomised, double-blind, placebo-controlled, phase 3 FREEDOM trial, postmenopausal women aged 60-90 years with osteoporosis were enrolled in 214 centres in North America, Europe, Latin America, and Australasia and were randomly assigned (1:1) to receive 60 mg subcutaneous denosumab or placebo every 6 months for 3 years. All participants who completed the FREEDOM trial without discontinuing treatment or missing more than one dose of investigational product were eligible to enrol in the open-label, 7-year extension, in which all participants received denosumab. The data represent up to 10 years of denosumab exposure for women who received 3 years of denosumab in FREEDOM and continued in the extension (long-term group), and up to 7 years for women who received 3 years of placebo and transitioned to denosumab in the extension (crossover group). The primary outcome was safety monitoring, comprising assessments of adverse event incidence and serious adverse event incidence, changes in safety laboratory analytes (ie, serum chemistry and haematology), and participant incidence of denosumab antibody formation. Secondary outcomes included new vertebral, hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine, total hip, femoral neck, and one-third radius. Analyses were done according to the randomised FREEDOM treatment assignments. All participants who received at least one dose of investigational product in FREEDOM or the extension were included in the combined safety analyses. All participants who enrolled in the extension with observed data were included in the efficacy analyses. The FREEDOM trial (NCT00089791) and its extension (NCT00523341) are both registered with ClinicalTrials.gov. FINDINGS: Between Aug 3, 2004, and June 1, 2005, 7808 women were enrolled in the FREEDOM study. 5928 (76%) women were eligible for enrolment in the extension, and of these, 4550 (77%) were enrolled (2343 long-term, 2207 crossover) between Aug 7, 2007, and June 20, 2008. 2626 women (1343 long-term; 1283 crossover) completed the extension. The yearly exposure-adjusted participant incidence of adverse events for all individuals receiving denosumab decreased from 165·3 to 95·9 per 100 participant-years over the course of 10 years. Serious adverse event rates were generally stable over time, varying between 11·5 and 14·4 per 100 participant-years. One atypical femoral fracture occurred in each group during the extension. Seven cases of osteonecrosis of the jaw were reported in the long-term group and six cases in the crossover group. The yearly incidence of new vertebral fractures (ranging from 0·90% to 1·86%) and non-vertebral fractures (ranging from 0·84% to 2·55%) remained low during the extension, similar to rates observed in the denosumab group during the first three years of the FREEDOM study, and lower than rates projected for a virtual long-term placebo cohort. In the long-term group, BMD increased from FREEDOM baseline by 21·7% at the lumbar spine, 9·2% at total hip, 9·0% at femoral neck, and 2·7% at the one-third radius. In the crossover group, BMD increased from extension baseline by 16·5% at the lumbar spine, 7·4% at total hip, 7·1% at femoral neck, and 2·3% at one-third radius. INTERPRETATION: Denosumab treatment for up to 10 years was associated with low rates of adverse events, low fracture incidence compared with that observed during the original trial, and continued increases in BMD without plateau. FUNDING: Amgen.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017. PMID: 28546097. doi:10.1016/S2213-8587(17)30138-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。